Bioethics, Ltd.
BOTH
$1.25
$0.70127.27%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 144.85% | 293.00% | 55.41% | 126.67% | 52.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.85% | 293.00% | 55.41% | 126.67% | 52.81% |
| Operating Income | -144.85% | -293.00% | -55.41% | -126.67% | -52.81% |
| Income Before Tax | -97.95% | -138.12% | -33.96% | -68.22% | -17.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -97.95% | -138.12% | -33.96% | -68.22% | -17.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.95% | -138.12% | -33.96% | -68.22% | -17.87% |
| EBIT | -144.85% | -293.00% | -55.41% | -126.67% | -52.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 12.56% | -138.78% | -34.32% | -67.79% | -18.13% |
| Normalized Basic EPS | 11.94% | -137.40% | -33.78% | -67.69% | -17.54% |
| EPS Diluted | 12.56% | -138.78% | -34.32% | -67.79% | -18.13% |
| Normalized Diluted EPS | 11.94% | -137.40% | -33.78% | -67.69% | -17.54% |
| Average Basic Shares Outstanding | 126.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 126.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |